U.S. pharma large copyright scrapped two experimental weight loss drugs final yr—a at the time-day by day pill, lotiglipron, resulting from elevated liver enzymes in addition to a 2 times-each day tablet, danuglipron, on account of robust side effects—but CEO Albert Bourla has mentioned the company is decided to “Perform and acquire” during